摘要
目的探讨对米氮平联合小剂量氨磺必利治疗抑郁症的临床效果和安全性。方法将64例符合《中国精神障碍分类与诊断标准(第3版)》(CCMD-3)诊断标准的抑郁症患者随机分为研究组和对照组,研究组给予米氮平和小剂量氨磺必利,对照组给予米氮平,分别治疗6周。采用汉密尔顿抑郁量表(HAMD)评定临床治疗效果,采用症状量表(TESS)评定不良反应。结果 2组治疗后HAMD评分均较治疗前显著下降(P<0.01);组间比较,治疗1周后,2组间HAMD评分差异无统计学意义(P>0.05),治疗2周、4周、6周后,研究组减分率均分别高于对照组(P<0.05)。治疗6周末,研究组显效率为87.50%,治疗组显效率为68.75%,2组显效率相比差异有统计学意义(P<0.05)。2组治疗各周TESS评分差异均无统计学意义(P>0.05)。结论米氮平联合小剂量氨磺必利治疗抑郁症比单用米氮平疗效更显著,且不增加不良反应。
Objective To determine the efficacy and safety of Mirtazapine combined with low-dose Amisulpride in the treatment of depression. Methods 64 patients who met CCMD-3 were assigned randomly into the experimental group or the control group. The experimental group was treated with Mirtazapine combined with low-dose Amisulpride, while the control group was treated with Mirtazapine for 6 weeks. Effects and side effects were evaluated separately with HAMD and TESS before and after the treatment. Results The scores of HAMD decreased significantly in both group after the treat- ment（ P 〈0.01 ）. At the end of the 1st week,the scores had no significant difference between the two groups. At the end of 2nd,4th and 6th week, the scores in the experimental group decreased more significantly than those in the other one （ P 〈 0.05 ）. The scores of TESS in both group had no significant difference （ P 〉 0.05 ）. Conclusion Mirtazapine com- bined with low-dose Amisulpride can improve the therapeutic effect more significantly and can be used safely.
出处
《中华全科医学》
2014年第5期721-722,共2页
Chinese Journal of General Practice
关键词
氨磺必利
米氮平
抑郁症
对照研究
Amisulpride
Mirtazapine
Depression
Control study
